CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Unity Biotechnology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Unity Biotechnology Inc
285 EAST GRAND AVENUE
Phone: (650) 416-1192p:650 416-1192 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: UBXUBX
On March 19, 2024, the Audit Committee of the Board of Directors of UNITY Biotechnology, Inc., after consultation with management, determined that the company incorrectly classified its warrants that were issued in August 2022 as equity which should have been recorded as liabilities and measured at fair value at each balance sheet date. As part of its determination, the Audit Committee concluded that it is appropriate to correct the accounting for the Warrants in the company’s financial statements for the year ended December 31, 2022 and the interim periods ended September 30, 2022, March 31, 2023, June 30, 2023, and September 30, 2023.
Business Summary
Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Keith R.Leonard 62 3/30/2020
Chief Executive Officer, Director AnirvanGhosh 59 3/30/2020 3/30/2020
Chief Financial Officer, Head of Corporate Development LynneSullivan 57 1/29/2021 8/1/2020
6 additional Officers and Directors records available in full report.

Business Names
Business Name
UBX
UNITY BIOTECHNOLOGY

General Information
Number of Employees: 19 (As of 12/31/2023)
Outstanding Shares: 16,786,647 (As of 4/11/2024)
Shareholders: 45
Stock Exchange: NASD
Federal Tax Id: 264726035
Fax Number: (302) 655-5049
Email Address: info@unitybiotechnology.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024